PPARG and lung carcinoma: PPARγ agonists have shown beneficial effects in anti-lung cancer, including disruption of tumor metabolic homeostasis, promotion of cell apoptosis, induction of cell cycle arrest, as well as inhibition of cell invasion and angiogenesis.